This Best Practice in Patient Recruitment report displays what percentages of patients are recruited from and where.
The stakes are high when it comes to clinical trials. Each day a trial goes beyond its intended deadline delays treatment for patients who would benefit from the medication and puts the sponsor organization at risk for lost revenue. Industry Standard Research’s Best Practices in Patient Recruitment report, based off of primary research with sponsors, CROs, and sites, includes an in-depth analysis of the industry’s strategies for completing a trial on-time and within budget.
One of the key findings in the report relates back to the use of specialized patient recruitment firms. According to both sponsors and CROs, engaging a specialized patient recruitment firm is a better value than adding more sites to the study. This is, in part, due to specialized recruitment firms having their own database of patients-one of the most important resources when recruiting for a clinical trial. As detailed in the chart below, the bulk of patients currently come from Existing patients at sites / in-house patient databases. While this is predicted to remain true for the next two years, respondents anticipate a smaller proportion of patients will come from in-house site databases by 2018.
“Currently, what percentage of your patients are recruited directly via the following sources? Your responses should add to 100%.”
ISR has collected additional insights to improve the efficacy of recruitment efforts in its Best Practices in Patient Recruitment report, including:
The Best Practices in Patient Recruitment is a valuable tool for anyone charged with patient recruitment. It will assist readers in knowing when and how to engage a specialized patient recruitment firm to get the best value and how to implement the best practices identified by industry peers to improve the likelihood of your trial finishing on-time and within budget. For more information about the report, please visit ISR’s report page at http://www.isrreports.com/reports/best-practices-patient-recruitment/
FDA Outlines Updated Requirement for Placebo-Controlled Trials in Vaccine Research
May 21st 2025In an article recently published by The New England Journal of Medicine, FDA higher-ups Vinay Prasad, MD, MPH; and Martin A. Makary, MD, MPH, wrote that any new COVID-19 vaccine must now be evaluated in placebo-controlled studies.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Full Phase IIIb BATURA Trial Results Show Airsupra Cuts Severe Exacerbations by 47% in Mild Asthma
May 20th 2025Results from the pivotal BATURA trial show that Airsupra (albuterol/budesonide) significantly outperformed albuterol monotherapy in reducing severe asthma exacerbations and systemic corticosteroid exposure, reinforcing its role as a next-generation, anti-inflammatory rescue therapy for mild asthma patients.